Effectiveness of Dienogest for Treatment of Recurrent Endometriosis: Multicenter Data

Lee JH, Jae Hoon Lee, Song JY, Jae Yen Song, Yi KW, Kyong Wook Yi, Sa Ra Lee, Lee SR, Lee DY, Dong‐Yun Lee, Dong-Yun Lee, Jung-Ho Shin, Jung‐Ho Shin, Shin JH, SiHyun Cho, Seok Kyo Seo, Sung Hoon Kim, Sung Kim, Kim SH
Reproductive sciences (Thousand Oaks, Calif.) · 2018 · vol. 25(10) , pp. 1515–1522 · doi:10.1177/1933719118779733 · PMID:29848190 · W2806443010
article OA: green CC0 ⤵ 30 in-corpus citations
🔓 Open OA copy Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06+body, 2026-06-16 ⓘ

This multicenter study evaluated dienogest in 121 women with recurrent endometriosis, finding significant reductions in pain, endometrioma size, and CA-125 levels after 24 weeks of treatment.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 · read from full text ⓘ

The paper evaluated the effectiveness and safety of dienogest (2 mg daily) in 121 women clinically diagnosed with recurrent endometriosis, treated for more than 24 weeks using multicenter data. Changes in endometriosis-associated pain measured by VAS, serum CA-125 levels, and recurrent endometrioma size were tracked, with findings that VAS pain scores significantly decreased from baseline to 24 weeks and that endometrioma size and CA-125 levels also significantly declined compared with baseline (with CA-125 reductions persisting to 72 weeks). Irregular bleeding was the most common adverse event, reported in about 30% of participants, and 42% overall experienced adverse events. This paper is centrally about endometriosis — it specifically assesses dienogest effectiveness for recurrent endometriosis across multiple centers.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

This study aimed to assess whether dienogest (DNG) is also effective in patients with recurrent endometriosis based on multicenter data of 121 women who were clinically diagnosed as having recurrent endometriosis and treated for more than 24 weeks with DNG (2 mg daily). We evaluated the changes in endometriosis-associated pain scores (visual analog scale [VAS]), serum cancer antigen 125 (CA-125) levels, and endometrioma sizes following DNG medication in these women along with adverse events associated with DNG medication. The mean duration of DNG treatment was 57.80 (24.08) weeks, and during continuation of DNG, the mean VAS score was 5.03 (1.73) at baseline and significantly decreased to 2.46 (1.32) at 24 weeks after taking DNG. In subgroup analysis, the trend of pain-related symptoms was compared between the symptom-only recurrence group and the recurrent endometrioma group. In both groups, the pain scores decreased significantly during the first 24 weeks but remained relatively unchanged thereafter. Moreover, the size of recurrent endometriomas and CA-125 levels also decreased significantly compared to baseline. The mean size of recurrent endometriomas was 3.77 (1.59) cm in diameter and decreased to 2.74 (1.53) cm after 24 weeks of DNG treatment ( P for trend < .001). The mean CA-125 level was 80.04 U/mL at baseline and significantly decreased to 33.11 U/mL after taking DNG for 24 weeks and lasted until 72 weeks ( P for trend = .0288). Overall, 51 (42.15%) patients reported adverse events, and the most common one was irregular bleeding pattern (29.75%, 36/121). In conclusion, DNG was found to be effective in reducing the size of endometriomas and provided symptomatic relief in this cohort of women with recurrent endometriosis.
Full text 2,496 characters · extracted from oa-html · click to expand
YUHASpace Repository 0 889 Cited 0 times in Cited 36 times in Effectiveness of Dienogest for Treatment of Recurrent Endometriosis: Multicenter Data - Authors - Jae Hoon Lee ; Jae Yen Song ; Kyong Wook Yi ; Sa Ra Lee ; Dong-Yun Lee ; Jung-Ho Shin ; SiHyun Cho ; Seok Kyo Seo ; Sung Hoon Kim - Citation - REPRODUCTIVE SCIENCES, Vol.25(10) : 1515-1522, 2018 - Journal Title - REPRODUCTIVE SCIENCES - ISSN - 1933-7191 - Issue Date - 2018 - Keywords - dienogest ; endometrioma ; endometriosis ; recurrence - Abstract - This study aimed to assess whether dienogest (DNG) is also effective in patients with recurrent endometriosis based on multicenter data of 121 women who were clinically diagnosed as having recurrent endometriosis and treated for more than 24 weeks with DNG (2 mg daily). We evaluated the changes in endometriosis-associated pain scores (visual analog scale [VAS]), serum cancer antigen 125 (CA-125) levels, and endometrioma sizes following DNG medication in these women along with adverse events associated with DNG medication. The mean duration of DNG treatment was 57.80 (24.08) weeks, and during continuation of DNG, the mean VAS score was 5.03 (1.73) at baseline and significantly decreased to 2.46 (1.32) at 24 weeks after taking DNG. In subgroup analysis, the trend of pain-related symptoms was compared between the symptom-only recurrence group and the recurrent endometrioma group. In both groups, the pain scores decreased significantly during the first 24 weeks but remained relatively unchanged thereafter. Moreover, the size of recurrent endometriomas and CA-125 levels also decreased significantly compared to baseline. The mean size of recurrent endometriomas was 3.77 (1.59) cm in diameter and decreased to 2.74 (1.53) cm after 24 weeks of DNG treatment ( P for trend < .001). The mean CA-125 level was 80.04 U/mL at baseline and significantly decreased to 33.11 U/mL after taking DNG for 24 weeks and lasted until 72 weeks ( P for trend = .0288). Overall, 51 (42.15%) patients reported adverse events, and the most common one was irregular bleeding pattern (29.75%, 36/121). In conclusion, DNG was found to be effective in reducing the size of endometriomas and provided symptomatic relief in this cohort of women with recurrent endometriosis. - Appears in Collections: - 1. College of Medicine (의과대학) > Dept. of Obstetrics and Gynecology (산부인과학교실) > 1. Journal Papers Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Endometriosis Hormone Antagonists Nandrolone Adult Amenorrhea Amenorrhea CA-125 Antigen CA-125 Antigen Endometriosis Endometriosis Endometriosis Female Hormone Antagonists Humans Multicenter Studies as Topic Nandrolone Nandrolone Pain Pain Pain Measurement

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (44)

Cited by (31)

Source provenance

europepmc
last seen: 2026-07-27T06:15:28.040536+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:19:43.094626+00:00
License: CC0 · commercial use OK